

Timolumab

Cat. No.:	HY-P99323
CAS No.:	1073538-99-4
Target:	AP-1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Timolumab (BTT1023), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023) could be used in the study of chronic inflammatory diseases ^{[1][2]} .
In Vitro	Timolumab (BTT1023) binds to human VAP-1, thereby blocking its function as an adhesion molecule. It also recognizes VAP-1 of other primates and rabbits but does not cross-react with rat or mouse. Timolumab (BTT1023) is potentially useful for the treatment and in vivo imaging of inflammatory conditions such as rheumatoid arthritis ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Ahmad H Ali, et al. Novel treatments in primary sclerosing cholangitis. Clin Liver Dis (Hoboken). 2016 Nov 30;8(5):132-135.
- [2]. Takayuki Inoue, et al. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem. 2013 Mar 1;21(5):1219-33.
- [3]. Anu Autio, et al. Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA